“Trials must take place in the state to qualify, and only companies or researchers with an investigational new drug (IND) application on file with the US Food and Drug Administration (FDA) are eligible for funding. Currently, that leaves only two known projects in the running: a treatment for spinal cord injury by Menlo Park–based Geron and a therapy for Stargardt’s macular dystrophy, a retinal disease, by Santa Monica–based Advanced Cell Technology.”Earlier, iPierian, Inc., of South San Francisco was identified as another potential applicant.
(The board discussion can be found beginning on page 41 of the meeting transcript.)
We are querying iPierian about its intentions.
Torres also interviewed the co-chair of iPierian's scientific advisory board concerning the CIRM program. Torres wrote,
Sphere: Related Content